Ocular Therapeutix, Inc. (FRA:0OT)

Market Cap	1.44B +17.2%
Revenue (ttm)	44.25M -18.5%
Net Income	-226.50M
EPS	-1.21
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	318
Open	5.89
Previous Close	5.78
Day's Range	5.89 - 6.11
52-Week Range	5.41 - 13.66
Beta	n/a
RSI	39.02
Earnings Date	Mar 6, 2026

About Ocular Therapeutix

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 325
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0OT

Financial Performance

In 2025, Ocular Therapeutix's revenue was $51.95 million, a decrease of -18.47% compared to the previous year's $63.72 million. Losses were -$265.94 million, 37.4% more than in 2024.

Financial numbers in USD